PureTech Health plc
Research PureTech Health plc (PRTC.L) on Bullrun: market cap GBX 26.43B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRTC.L
- ExchangeLSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 26.43B
- Financial periodFY2025
- RevenueUSD 4.66M
- Revenue growth8.0%
- Net income-USD 109.74M
- Free cash flow-USD 85.14M
Valuation Snapshot
latest market cap is GBX 26.43B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.66M | -USD 109.74M | -USD 85.14M | n/a | -0.46 | USD 252.47M | USD 19.59M | USD 312.07M |
| FY2024 | USD 4.32M | USD 53.51M | -USD 134.38M | n/a | 0.21 | USD 280.64M | USD 22.36M | USD 414.71M |
| FY2023 | USD 750.00K | -USD 65.70M | -USD 106.16M | n/a | -0.24 | USD 191.08M | USD 25.34M | USD 464.07M |
| FY2022 | USD 2.09M | -USD 50.35M | -USD 180.97M | n/a | -0.18 | USD 149.87M | USD 46.87M | USD 542.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 26.43B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PureTech Health plc's market cap?
PureTech Health plc's market capitalization is GBX 26.43B.
What does PureTech Health plc do?
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.